Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet
- PMID: 14747225
- DOI: 10.2337/diacare.27.2.436
Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet
Abstract
Objective: To investigate the tolerability, efficacy, and mode of action of Caiapo, an extract of white sweet potatoes, on metabolic control in type 2 diabetic patients.
Research design and methods: A total of 61 type 2 diabetic patients treated by diet were given 4 g Caiapo (n = 30; mean age 55.2 +/- 2.1 years; BMI 28.0 +/- 0.4 kg/m(2)) or placebo (n = 31; mean age 55.6 +/- 1.5 years; BMI 27.6 +/- 0.3 kg/m(2)) once daily for 12 weeks. Each subject underwent a 75-g oral glucose tolerance test (OGTT) at baseline and after 1, 2, and 3 months to assess 2-h glucose levels. Additionally, fasting blood glucose, HbA(1c), total cholesterol, and triglyceride levels were measured.
Results: After treatment with Caiapo, HbA(1c) decreased significantly (P < 0.001) from 7.21 +/- 0.15 to 6.68 +/- 0.14%, whereas it remained unchanged (P = 0.23) in subjects given placebo (7.04 +/- 0.17 vs. 7.10 +/- 0.19%). Fasting blood glucose levels decreased (P < 0.001) in the Caiapo group (143.7 +/- 1.9 vs. 128.5 +/- 1.7 mg/dl) and did not change in the placebo group (144.3 +/- 1.9 vs. 138.2 +/- 2.1 mg/dl; P = 0.052). A decrease in body weight was observed in both the placebo group (P = 0.0027) and in the Caiapo group (P < 0.0001), probably due to a better- controlled lifestyle. In the Caiapo group, body weight was related to the improvement in glucose control (r = 0.618; P < 0.0002). Two-hour glucose levels were significantly (P < 0.001) decreased in the Caiapo group (193.3 +/- 10.4 vs. 162.8 +/- 8.2 mg/dl) compared with the placebo group (191.7 +/- 9.2 vs. 181.0 +/- 7.1 mg/dl). Mean cholesterol at the end of the treatment was significantly lower in the Caiapo group (214.6 +/- 11.2 mg/dl) than in the placebo group (248.7 +/- 11.2 mg/dl; P < 0.05). No significant changes in triglyceride levels or blood pressure were observed, and Caiapo was well tolerated without significant adverse effects.
Conclusions: This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes. For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c). Thus, the neutraceutical Caiapo seems to be a useful agent in the treatment of type 2 diabetes.
Similar articles
-
Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patients.Metabolism. 2003 Jul;52(7):875-80. doi: 10.1016/s0026-0495(03)00073-8. Metabolism. 2003. PMID: 12870164 Clinical Trial.
-
Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects.Diabetes Obes Metab. 2008 Jul;10(7):586-92. doi: 10.1111/j.1463-1326.2007.00752.x. Epub 2007 Jul 21. Diabetes Obes Metab. 2008. PMID: 17645559 Clinical Trial.
-
Bromocriptine: a novel approach to the treatment of type 2 diabetes.Diabetes Care. 2000 Aug;23(8):1154-61. doi: 10.2337/diacare.23.8.1154. Diabetes Care. 2000. PMID: 10937514 Clinical Trial.
-
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Clin Ther. 2008. PMID: 18803987 Clinical Trial.
-
Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.Clin Ther. 2007 Jan;29(1):74-83. doi: 10.1016/j.clinthera.2007.01.003. Clin Ther. 2007. PMID: 17379048 Clinical Trial.
Cited by 11 articles
-
Comparative study on antidiabetic, cytotoxicity, antioxidant and antibacterial properties of biosynthesized silver nanoparticles using outer peels of two varieties of Ipomoea batatas (L.) Lam.Int J Nanomedicine. 2019 Jul 2;14:4741-4754. doi: 10.2147/IJN.S210517. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31456635 Free PMC article.
-
Natural Hydrogen Sulfide Donors from Allium sp. as a Nutraceutical Approach in Type 2 Diabetes Prevention and Therapy.Nutrients. 2019 Jul 12;11(7):1581. doi: 10.3390/nu11071581. Nutrients. 2019. PMID: 31336965 Free PMC article. Review.
-
Anthocyanins in the Management of Metabolic Syndrome: A Pharmacological and Biopharmaceutical Review.Front Pharmacol. 2018 Dec 4;9:1310. doi: 10.3389/fphar.2018.01310. eCollection 2018. Front Pharmacol. 2018. PMID: 30564116 Free PMC article. Review.
-
Evaluation of antidiabetic activity of Ipomoea batatas L. extract in alloxan-induced diabetic rats.Int J Immunopathol Pharmacol. 2018 Mar-Dec;32:2058738418814678. doi: 10.1177/2058738418814678. Int J Immunopathol Pharmacol. 2018. PMID: 30477357 Free PMC article.
-
Characterization of Secondary Metabolites from Purple Ipomoea batatas Leaves and Their Effects on Glucose Uptake.Molecules. 2016 Jun 8;21(6):745. doi: 10.3390/molecules21060745. Molecules. 2016. PMID: 27338312 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Medical
-
Miscellaneous